ANNEX I

SUMMARY OF PRODUCT CHARACTERISTICS

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

BTVPUR suspension for injection for sheep and cattle.

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Each dose of 1 ml contains:

Active substances *:
Inactivated bluetongue virus ..... ≥ strain specific pass level (log10 pixels) **
(*) maximum of two different inactivated bluetongue virus serotypes

(**)Strain-specific pass levels	(**) Antigen content (VP2 protein) by immuno-assay
BTV1	1.9 log10 pixels/mL
BTV2	1.82 log10 pixels/mL
BTV4	1.86 log10 pixels/mL
BTV8	2.12 log10 pixels/mL

A confirmatory final potency test by seroneutralisation in rats is conducted when a batch is released.

Adjuvants:
Al^{3+} (as hydroxide) 2.7 mg
Saponin 30 HU**
(**) Haemolytic units

For the full list of excipients, see section 6.1.

The type of strain(s) (two strains at most) included in the final product will be selected based on the epidemiological situation at the time of manufacturing and will be stated on the label.

3. PHARMACEUTICAL FORM

Suspension for injection
Appearance: homogeneous milky white .

4. CLINICAL PARTICULARS

4.1 Target species

Sheep and cattle

4.2 Indications for use, specifying the target species

Active immunisation of sheep to prevent viraemia* and to reduce clinical signs caused by bluetongue virus serotypes 1, 2, 4 and/or 8 (combination of maximum 2 serotypes).
Active immunisation of cattle to prevent viraemia* caused by bluetongue virus serotypes 1, 2, 4 and/or 8, and to reduce clinical signs caused by bluetongue virus serotypes 1, 4 and/or 8 (combination of maximum 2 serotypes).
*below the level of detection by the validated RT-PCR method at 3.68 $\log_{10}$ RNA copies/ml, indicating no infectious virus transmission.

Onset of immunity has been demonstrated 3 weeks (or 5 weeks in sheep for BTV2) after the primary vaccination course for BTV-1, BTV-2 (cattle), BTV-4 and BTV-8 serotypes.
The duration of immunity for cattle and sheep is 1 year after primary vaccination course.

4.3 Contraindications

None.

4.4 Special warnings for each target species

Vaccinate healthy animals only.

If used in other domestic and wild ruminant species that are considered at risk of infection, its use in these species should be undertaken with care and it is advisable to test the vaccine on a small number of animals prior to mass vaccination. The level of efficacy for other species may differ from that observed in sheep and cattle.

4.5 Special precautions for use

Special precautions for use in animals

Not applicable.

Special precautions to be taken by the person administering the veterinary medicinal product to animals

None

4.6 Adverse reactions (frequency and seriousness)

In very rare cases it has been observed a small local swelling at the injection site (at most 32 cm^2 in cattle and 24 cm^2 in sheep) which becomes residual 35 days later ($\leq$ 1 cm^2).

In very rare cases a transient increase in body temperature, normally not exceeding an average of 1.1ºC, may occur within 24 hours after vaccination.

The frequency of adverse reactions is defined using the following convention:
- very common (more than 1 in 10 animals treated displaying adverse reaction(s))
- common (more than 1 but less than 10 animals in 100 animals treated)
- uncommon (more than 1 but less than 10 animals in 1,000 animals treated)
- rare (more than 1 but less than 10 animals in 10,000 animals treated)
- very rare (less than 1 animal in 10,000 animals treated, including isolated reports).

4.7 Use during pregnancy, lactation or lay

Can be used during pregnancy and lactation.

The safety and the efficacy of the vaccine have not been established in breeding males. In this category of animals the vaccine should be used only according to the benefit/risk assessment by the responsible veterinarian and/ or national Competent Authorities on the current vaccination policies against Bluetongue Virus (BTV).

4.8 Interaction with other medicinal products and other forms of interaction

No information is available on the safety and efficacy of this vaccine when used with any other veterinary medicinal product. A decision to use this vaccine before or after any other veterinary medicinal product therefore needs to be made on a case by case basis.

4.9 Amounts to be administered and administration route

Apply usual aseptic procedures.

Shake gently immediately before use. Avoid bubble formation, as this can be irritating at the site of injection. The entire content of the bottle should be used immediately after broaching and during the same procedure. Avoid multiple vial broaching.

Administer one dose of 1 ml subcutaneously according to the following vaccination scheme:

- **Primary vaccination**

In sheep:
- First injection: from 1 month of age in naive animals (or from 2.5 months of age in young animals born to immune sheep).
- Second injection: after 3-4 weeks.
  For a monovalent vaccine containing an inactivated Bluetongue Virus serotype 2 or 4, or for a bivalent vaccine containing both serotypes 2 and 4 together, one injection is sufficient.

In cattle:
- First injection: from 1 month of age in naive animals (or from 2.5 months of age in young animals born to immune cattle).
- Second injection: after 3-4 weeks.

- **Revaccination**

Annual.

4.10 Overdose (symptoms, emergency procedures, antidotes), if necessary

Very rare and transient apathy can be observed after the administration of a double-dose of the vaccine. No other adverse reactions except those mentioned in section 4.6 were observed.

4.11 Withdrawal period(s)

Zero days.

5. IMMUNOLOGICAL PROPERTIES

Pharmacotherapeutic group: bluetongue virus vaccine, ATC vet code QI04AA02 (sheep) and QI02AA08 (cattle).

The vaccine contains inactivated Bluetongue Virus with aluminium hydroxide and saponin adjuvants. It induces an active and specific immunity against bluetongue virus in the vaccinated animal.

6. PHARMACEUTICAL PARTICULARS

6.1 List of excipients

Silicon antifoam
Phosphate buffer
Glycine buffer
Aluminium hydroxide
Saponin

6.2 Major incompatibilities

Do not mix with any other veterinary medicinal product.

6.3 Shelf life

Shelf life of monovalent or bivalent formulation with Bluetongue Virus serotypes 1, 8 (100 ml, 50 ml and 10 ml bottles) and/or 2, 4 (100 ml and 50 ml bottles): 2 years.
Shelf life of monovalent or bivalent formulation with Bluetongue Virus serotypes 2 and/or 4 (10 ml bottles): 18 months.
Shelf life after first opening the immediate packaging: use immediately.

6.4 Special precautions for storage

Store and transport refrigerated (2 ºC – 8 ºC).
Do not freeze.
Protect from light.

6.5 Nature and composition of immediate packaging

Polypropylene bottle of 50 or 100 ml with butyl elastomer closure.
Box of 1 bottle of 100 doses (1 x 100 ml)
Box of 10 bottles of 100 doses (10 x 100 ml)
Box of 1 bottle of 50 doses (1 x 50 ml)
Box of 10 bottles of 50 doses (10 x 50 ml)

Type I glass bottle of 10 ml with butyl elastomer closure.
Box of 1 bottle of 10 doses (1 x 10 ml)

6.6 Special precautions for the disposal of unused veterinary medicinal product or waste materials derived from the use of such products

Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements.

7. MARKETING AUTHORISATION HOLDER

Boehringer Ingelheim Vetmedica GmbH
55216 Ingelheim/Rhein
GERMANY

8. MARKETING AUTHORISATION NUMBER(S)

EU/2/10/113/001-050

9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

Date of first authorisation: 17/12/2010
Date of last renewal: 08/09/2015

10. DATE OF REVISION OF THE TEXT

Detailed information of this veterinary medicinal product is available on the website of the European Medicines Agency (http://www.ema.europa.eu).

PROHIBITION OF SALE, SUPPLY AND/OR USE

Any person intending to manufacture, import, possess, sell, supply and use of BTVPUR containing serotypes 1, 2, 4 and 8 must first consult the relevant Member State's competent authority on the current vaccination policies, as these activities may be prohibited in a Member State on the whole or part of its territory pursuant to national legislation.

ANNEX II

A. MANUFACTURER OF THE BIOLOGICAL ACTIVE SUBSTANCE AND MANUFACTURER RESPONSIBLE FOR BATCH RELEASE

B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY OR USE

C. STATEMENT OF THE MRLs

A. MANUFACTURER OF THE BIOLOGICAL ACTIVE SUBSTANCE AND MANUFACTURER RESPONSIBLE FOR BATCH RELEASE

Name and address of the manufacturers of the biological active substance

BOEHRINGER INGELHEIM Animal Health UK Limited
Biological Laboratory, Ash Road,
Pirbright, Woking, Surrey GU24 0NQ
United Kingdom

Boehringer Ingelheim Animal Health France SCS
Laboratoire Lyon Gerland
254, rue Marcel Mérieux
69007 LYON
France

For viral culture, inactivation and concentration steps only:
Boehringer Ingelheim Animal Health France SCS
4 Chemin du Calquet
31000 TOULOUSE
France

For purification and bottling steps only:
Boehringer Ingelheim Animal Health France SCS
Laboratoire Porte des Alpes
Rue de l'Aviation
69800 Saint-Priest
France

Name and address of the manufacturer responsible for batch release

Boehringer Ingelheim Animal Health France SCS
Laboratoire Porte des Alpes
Rue de l'Aviation
69800 Saint-Priest
France

B. CONDITIONS OR RESTRICTIONS OF REGARDING SUPPLY OR USE

Veterinary medicinal product subject to prescription.

According to Article 71 of Directive 2001/82/EC of the European Parliament and of the Council as amended, a Member State may, in accordance with its national legislation, prohibit the manufacture, import, possession, sale, supply and/or use of immunological veterinary medicinal products on the whole or part of its territory if it is established that:

a) the administration of the product to animals will interfere with the implementation of a national programme for the diagnosis, control or eradication of animal diseases, or will cause difficulties in certifying the absence of contamination in live animals or in foodstuffs or other products obtained from treated animals.

b) the disease to which the product is intended to confer immunity is largely absent from the territory in question.

The use of this veterinary medicinal product is only allowed under the particular conditions established by European Community legislation on the control of Bluetongue.

C. STATEMENT OF THE MRLs

The active substance being a principle of biological origin intended to produce active immunity is not within the scope of Regulation (EC) No 470/2009.

The excipients (including adjuvants) listed in section 6.1 of the SPC are either allowed substances for which table 1 of the annex to Commission Regulation (EU) No 37/2010 indicates that no MRLs are required.

ANNEX III

LABELLING AND PACKAGE LEAFLET

A. LABELLING

PARTICULARS TO APPEAR ON THE OUTER PACKAGE
Box of 1 bottle of 10 ml,
Box of 1 bottle of 50 ml,
Box of 10 bottles of 50 ml,
Box of 1 bottle of 100 ml,
Box of 10 bottles of 100 ml

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

BTVPUR suspension for injection for sheep and cattle

2. STATEMENT OF ACTIVE SUBSTANCES

Each dose of 1 ml contains:
Active substances *:

Inactivated Bluetongue Virus .....≥ strain specific pass level (log_{10} pixels) **
* maximum of two different inactivated bluetongue virus serotypes

(**)Strain-specific pass levels	(**) Antigen content (VP2 protein) by immuno-assay
BTV1	1.9 log10 pixels/mL
BTV2	1.82 log10 pixels/mL
BTV4	1.86 log10 pixels/mL
BTV8	2.12 log10 pixels/mL

A confirmatory final potency test by seroneutralisation in rats is conducted when a batch is released

3. PHARMACEUTICAL FORM

Suspension for injection

4. PACKAGE SIZE

10 doses (10 ml)
50 doses (50 ml)
10 x 50 doses (10 x 50 ml)
100 doses (100 ml)
10 x 100 doses (10 x100 ml)

5. TARGET SPECIES

Sheep and cattle

6. INDICATION(S)

7. METHOD AND ROUTE(S) OF ADMINISTRATION

Subcutaneous use.
Read the package leaflet before use.

8. WITHDRAWAL PERIOD(S)

Withdrawal period: zero days.

9. SPECIAL WARNING(S), IF NECESSARY

10. EXPIRY DATE

EXP {month/year}
Once broached, use immediately.

11. SPECIAL STORAGE CONDITIONS

Store and transport refrigerated.
Do not freeze.
Protect from light.

12. SPECIFIC PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCTS OR WASTE MATERIALS, IF ANY

Disposal: read package leaflet

13. THE WORDS "FOR ANIMAL TREATMENT ONLY" AND CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE, IF APPLICABLE

For animal treatment only. To be supplied only on veterinary prescription.

14. THE WORDS "KEEP OUT OF THE SIGHT AND REACH OF CHILDREN"

Keep out of the sight and reach of children.

15. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER

Boehringer Ingelheim Vetmedica GmbH
55216 Ingelheim/Rhein
GERMANY

16. MARKETING AUTHORISATION NUMBER(S)

EU/2/10/113/001-050

17. MANUFACTURER'S BATCH NUMBER

Lot {number}

MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS

Bottle of 10 and 50 ml

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

BTVPUR suspension for injection for sheep and cattle

2. QUANTITY OF THE ACTIVE SUBSTANCE(S)

1 ml dose*:
Inactivated BTV1 .....≥ 1.9 log10 pixels
Inactivated BTV2 .....≥ 1.82 log10 pixels
Inactivated BTV4 .....≥ 1.86 log10 pixels
Inactivated BTV8 .....≥ 2.12 log10 pixels
(*) maximum of two different inactivated bluetongue virus serotypes.

3. CONTENTS BY WEIGHT, BY VOLUME OR BY NUMBER OF DOSES

10 doses (10 ml)
50 doses (50 ml)

4. ROUTE(S) OF ADMINISTRATION

SC

5. WITHDRAWAL PERIOD(S)

Withdrawal period: zero days.

6. BATCH NUMBER

Lot {number}

7. EXPIRY DATE

EXP {month/year}
Once broached, use immediately.

8. THE WORDS "FOR ANIMAL TREATMENT ONLY"

For animal treatment only.

PARTICULARS TO APPEAR ON THE IMMEDIATE PACKAGE

Bottle of 100 ml

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

BTVPUR suspension for injection for sheep and cattle

2. STATEMENT OF ACTIVE SUBSTANCES

Each dose of 1 ml contains:
Active substances *:

Inactivated Bluetongue Virus .....≥ strain specific pass level (log_{10} pixels) **
* maximum of two different inactivated bluetongue virus serotypes

(**)Strain-specific pass levels	(**) Antigen content (VP2 protein) by immuno-assay
BTV1	1.9 log10 pixels/mL
BTV2	1.82 log10 pixels/mL
BTV4	1.86 log10 pixels/mL
BTV8	2.12 log10 pixels/mL

A confirmatory final potency test by seroneutralisation in rats is conducted when a batch is released

3. PHARMACEUTICAL FORM

Suspension for injection

4. PACKAGE SIZE

100 doses (100 ml)

5. TARGET SPECIES

Sheep and cattle

6. INDICATION(S)

7. METHOD AND ROUTE(S) OF ADMINISTRATION

Subcutaneous use.
Read the package leaflet before use.

8. WITHDRAWAL PERIOD(S)

Withdrawal period: zero days

9. SPECIAL WARNING(S), IF NECESSARY

10. EXPIRY DATE

EXP {month/year}
Once broached, use immediately.

11. SPECIAL STORAGE CONDITIONS

Store and transport refrigerated.
Do not freeze.
Protect from light.

12. SPECIFIC PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCTS OR WASTE MATERIALS, IF ANY

13. THE WORDS "FOR ANIMAL TREATMENT ONLY" AND CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE, IF APPLICABLE

For animal treatment only. To be supplied only on veterinary prescription.

14. THE WORDS "KEEP OUT OF THE SIGHT AND REACH OF CHILDREN"

Keep out of the sight and reach of children.

15. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER

Boehringer Ingelheim Vetmedica GmbH
55216 Ingelheim/Rhein
GERMANY

16. MARKETING AUTHORISATION NUMBER(S)

EU/2/10/113/001-050

17. MANUFACTURER'S BATCH NUMBER

Lot {number}

B. PACKAGE LEAFLET

PACKAGE LEAFLET:
BTVPUR suspension for injection for sheep and cattle

1. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER AND OF THE MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE, IF DIFFERENT

Marketing authorisation holder:
Boehringer Ingelheim Vetmedica GmbH
55216 Ingelheim/Rhein
GERMANY

Manufacturer responsible for batch release:
Boehringer Ingelheim Animal Health France SCS
Laboratoire Porte des Alpes
Rue de l'Aviation
69800 Saint-Priest
France

2. NAME OF THE VETERINARY MEDICINAL PRODUCT

BTVPUR suspension for injection for sheep and cattle

3. STATEMENT OF THE ACTIVE SUBSTANCE(S) AND OTHER INGREDIENT(S)

Each dose of 1 ml contains:

Active substance*:

Inactivated Bluetongue Virus .....≥ strain specific pass level (log_{10} pixels) **
* maximum of two different inactivated bluetongue virus serotypes

(**)Strain-specific pass levels	(**) Antigen content (VP2 protein) by immuno-assay
BTV1	1.9 log10 pixels/mL
BTV2	1.82 log10 pixels/mL
BTV4	1.86 log10 pixels/mL
BTV8	2.12 log10 pixels/mL

A confirmatory final potency test by seroneutralisation in rats is conducted when a batch is released.

Adjuvants:
Al3+ (as hydroxide) ..... 2.7 mg
Saponin.....30 HU**
(**)Haemolytic units

The type of strain(s) (two strains at most) included in the final product will be selected based on the epidemiological situation at the time of manufacturing and will be stated on the label.

Appearance: homogeneous milky white.

4. INDICATION(S)

Active immunisation of sheep to prevent viraemia* and to reduce clinical signs caused by Bluetongue Virus Serotypes 1, 2, 4 and/or 8 (combination of maximum 2 serotypes).

Active immunisation of cattle to prevent viraemia* caused by bluetongue virus serotypes 1, 2, 4 and/or 8, and to reduce clinical signs caused by bluetongue virus serotypes 1, 4 and/or 8 (combination of maximum 2 serotypes).
*below the level of detection by the validated RT-PCR method at 3.68 $\log_{10}$ RNA copies/ml, indicating no infectious virus transmission.

Onset of immunity has been demonstrated 3 weeks (or 5 weeks in sheep for BTV2) after the primary vaccination course for BTV1, BTV2 (cattle), BTV-4 and BTV-8 serotypes.

The duration of immunity for cattle and sheep is 1 year after primary vaccination course.

5. CONTRAINDICATIONS

None.

6. ADVERSE REACTIONS

In very rare cases it has been observed a small local swelling at the injection site (at most 32 cm² in cattle and 24 cm² in sheep) which becomes residual 35 days later (≤ 1 cm^2).

In very rare cases a transient increase in body temperature, normally not exceeding an average of 1.1 ºC, may occur within 24 hours after vaccination.

The frequency of adverse reactions is defined using the following convention:
- very common (more than 1 in 10 animals treated displaying adverse reaction(s))
- common (more than 1 but less than 10 animals in 100 animals treated)
- uncommon (more than 1 but less than 10 animals in 1,000 animals treated)
- rare (more than 1 but less than 10 animals in 10,000 animals treated)
- very rare (less than 1 animal in 10,000 animals treated, including isolated reports).

If you notice any side effects, even those not already listed in this package leaflet or you think that the medicine has not worked, please inform your veterinary surgeon.

7. TARGET SPECIES

Sheep and cattle.

8. DOSAGE FOR EACH SPECIES, ROUTE(S) AND METHOD OF ADMINISTRATION

Administer one dose of 1 ml subcutaneously according to the following vaccination scheme:

- **Primary vaccination**

In sheep

- 1st injection: from 1 month of age in naive animals (or from 2.5 months of age in young animals born to immune sheep).
- 2nd injection: after 3-4 weeks

For a monovalent vaccine containing an inactivated Bluetongue Virus serotypes 2 or 4, or for a bivalent vaccine containing both serotypes 2 and 4 together, one injection is sufficient.

In cattle

- 1st injection: from 1 month of age in naive animals (or from 2.5 months of age in young animals born to immune cattle).
- 2nd injection: after 3-4 weeks.

- **Revaccination**

Annual.

9. ADVICE ON CORRECT ADMINISTRATION

Apply usual aseptic procedures.

Shake gently immediately before use. Avoid bubble formation, as this can be irritating at the site of injection. The entire content of the bottle should be used immediately after broaching and during the same procedure. Avoid multiple vial broaching.

10. WITHDRAWAL PERIOD(S)

Zero days.

11. SPECIAL STORAGE PRECAUTIONS

Keep out of the sight and reach of children.

Store and transport refrigerated (2 ºC – 8 ºC).
Do not freeze.
Protect from light.

Shelf life after first opening the immediate packaging: use immediately.
Do not use this veterinary medicinal product after the expiry date which is stated on the carton after EXP.

12. SPECIAL WARNING(S)

Special warnings for each target species:
Vaccinate healthy animals only.
If used in other domestic and wild ruminant species that are considered at risk of infection, its use in these species should be undertaken with care and it is advisable to test the vaccine on a small number of animals prior to mass vaccination. The level of efficacy for other species may differ from that observed in sheep and cattle.

Special precautions for use in animals:
Not applicable.

Pregnancy and lactation:
Can be used during pregnancy and lactation.

Fertility:
The safety and the efficacy of the vaccine have not been established in breeding males. In this category of animals the vaccine should be used only according to the benefit/risk assessment by the responsible veterinarian and/or national Competent Authorities on the current vaccination policies against Bluetongue Virus (BTV).

Interaction with other medicinal products and other forms of interaction:
No information is available on the safety and efficacy of this vaccine when used with any other veterinary medicinal product. A decision to use this vaccine before or after any other veterinary medicinal product therefore needs to be decided on a case by case basis.

Overdose (symptoms, emergency procedures, antidotes):
Very rare and transient apathy can be observed after the administration of a double-dose of the vaccine. No other adverse reactions except those mentioned in section ‘Adverse Reactions’ were observed.

Incompatibilities:
Do not mix with any other veterinary medicinal product.

13. SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCT OR WASTE MATERIALS, IF ANY

Medicines should not be disposed of via wastewater or household waste.
Ask your veterinary surgeon how to dispose of medicines no longer required. These measures should help to protect the environment.

14. DATE ON WHICH THE PACKAGE LEAFLET WAS LAST APPROVED

Detailed information on this veterinary medicinal product is available on the website of the European Medicines Agency http://www.ema.europa.eu.

15. OTHER INFORMATION

The vaccine contains inactivated Bluetongue Virus with aluminium hydroxide and saponin adjuvants. It induces an active and specific immunity against Bluetongue Virus in the vaccinated animal.

Not all pack sizes may be marketed
Box of 1 bottle of 10 doses (1 x 10 ml)
Box of 1 bottle of 50 doses (1 x 50 ml)
Box of 10 bottles of 50 doses (10 x 50 ml)
Box of 1 bottle of 100 doses (1 x 100 ml)
Box of 10 bottles of 100 doses (10 x 100 ml)

Any person intending to manufacture, import, possess, sell, supply and use of BTVPUR containing serotypes 1, 2, 4 and 8 must first consult the relevant Member State's competent authority on the current vaccination policies, as these activities may be prohibited in a Member State on the whole or part of its territory pursuant to national legislation.